Tumour Analysis-Lynch Syndrome Dr Alan Donaldson Consultant in Clinical Genetics Bristol.
-
Upload
loren-patrick -
Category
Documents
-
view
217 -
download
0
Transcript of Tumour Analysis-Lynch Syndrome Dr Alan Donaldson Consultant in Clinical Genetics Bristol.
Tumour Analysis-Lynch Syndrome
Dr Alan DonaldsonConsultant in Clinical Genetics
Bristol
Why do tumour analysis?
• To identify 1-5% of individuals whose colon cancer may be due to Lynch syndrome, for DNA analysis.
• ~15% of colon cancers are MSI high.– Generally have a better outcome.– Poorer response to 5 Fluorouracil?
Lynch Syndrome.Hereditary non polyposis colorectal cancer – HNPCC.
• Autosomal Dominant disorder.• Due to mutations in one of the mismatch repair
genes.– MSH2 50%– MLH1 40%– MSH6 ~7%– PMS2 <5%– (TACSD1) ~1-2%
• Accounts for 1-5% of all colon cancers.
Mismatch repair function.MSH6 MSH2 MSH3
TTT TTTT TTT TTTTTTTTTTTTT TTTTTTTTTTTTTT
PMS2 MLH1
HmutSHmutS
HmutLPMS1
MLH3?
Amsterdam Criteria• Three or more family members, one of whom is a first degree relative of
the other two, with HNPCC-related cancers*.
• Two successive affected generations.
• One or more of the HNPCC-related cancers diagnosed before age 50 years.
• Exclusion of (FAP).
* Colon, endometrial, small intestine, hepatobiliary, urinary tract.
Immunohistochemical (IHC) staining of the mismatch repair proteins.
MLH1 PMS2
MSH2 MSH6
Microsatellite instability (MSI) 1.
Normal tissue
Tumour tissue
Arrows indicated additional peaksand microsatellite instability.
Sporadic loss of MLH1.
• 10-15% of all colorectal cancers.
• Associated with DNA methylation.
• Associated with BrafV600E in colonic tumours, but not endometrial.
Advantages / disadvantages of MSI.
Advantages.• Better sensitivity & Specificity than IHC.• Able to detect BRAFV600E mutations.
Disadvantages.• More expensive than IHC.• Doesn’t tell you what gene is involved.
Who is ordering these tests?
Genetics
Dermatology
Oncology
Gynaecology
Surgery?
Pathology?
Any Questions?